Advertisement
Letter to the Editor| Volume 88, ISSUE 3, P431-432, September 2013

Re: Letter in response to “Neuropathy Associated with Etonogestrel Implant Insertion”

      I welcome the correspondence highlighting Implanon insertion site advances, namely the avoidance of the intermuscular groove between biceps and triceps. The official Nexplanon UK on-line insertion guide currently advises insertion “8–10 cm above the medial epicondyle…to minimize the risk of neurovascular damage” [ ]. This insertion guide makes no reference to the biceps/triceps groove. The manufacturer revised the Summary of Product Characteristics in 2007, deleting reference to this groove [
      • Rowlands S.
      Legal aspects of contraceptive implants.
      , ]. The manufacturer's instruction to insert in the region 8–10 cm above, or proximal, to the medial epicondyle avoids this groove by lying posterior to it, albeit by a rather small distance. Insertion over the anteromedial aspect of biceps was recommended by Bragg et al. [
      • Bragg T.W.H.
      • Jose R.M.
      • Bland J.W.
      • Matthews R.N.
      • Srivastava S.
      Implantable contraceptive devices: primum non nocere.
      ]; however, this site will likely produce a less concealed scar. Palpating the brachial artery can be used as an anatomical marker for the neurovascular bundle, with insertion performed a suitable distance anterior or posterior to this. Nexplanon provides a redesigned applicator when compared to its predecessor Implanon; however, this does not influence choice of insertion site. Although not compulsory, it is strongly advised that healthcare professionals receive official Nexplanon training in appropriate insertion and removal techniques to avoid damage to neural and vascular structures.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. http://www.nexplanon.co.uk/173/Inserting-the-Nexplanon-implant [accessed 22nd October 2012].

        • Rowlands S.
        Legal aspects of contraceptive implants.
        J Fam Plann Reprod Health Care. 2010; 36: 243-248
      2. http://www.medicines.org.uk/EMC/medicine/23824/SPC/Nexplanon%2068%20mg%20implant%20for%20subdermal%20use/#POSOLOGY [accessed 22nd October 2012].

        • Bragg T.W.H.
        • Jose R.M.
        • Bland J.W.
        • Matthews R.N.
        • Srivastava S.
        Implantable contraceptive devices: primum non nocere.
        J Fam Plann Reprod Health Care. 2006; 32: 190-192